Please check your internet connection and try again.
## Mega%252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252520cv
### Overview
Mega%252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252520cv is a potent cardiovascular agent with a mechanism of action that involves significant vasodilatory and positive inotropic effects. Its primary role is to improve hemodynamic parameters in critical care settings.
### Primary Indications
* Management of cardiogenic shock.
* Treatment of severe hypotension refractory to other vasopressors.
* Support of cardiac output in patients with acutely decompensated heart failure.
### Adult Dosing
The initial dose is typically 2-10 mcg/kg/min intravenously, titrated to achieve desired hemodynamic goals (e.g., mean arterial pressure > 65 mmHg, improved cardiac index). Doses may be escalated up to 20 mcg/kg/min based on patient response and tolerance.
### Pediatric Dosing
There is limited established pediatric dosing for Mega%252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252520cv. Dosing should be guided by local protocol, expert consultation, and careful hemodynamic monitoring, often starting at lower doses (e.g., 1-5 mcg/kg/min) and titrating cautiously.
### Dose Adjustments
* **Renal Impairment:** No specific dose adjustment is universally recommended, but caution and close monitoring are advised as renally excreted metabolites may accumulate.
* **Hepatic Impairment:** No specific dose adjustment is universally recommended, but caution and close monitoring are advised due to potential alterations in metabolism and clearance.
### Contraindications
* Known hypersensitivity to Mega%252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252520cv or its components.
* Severe aortic stenosis or hypertrophic obstructive cardiomyopathy where vasodilation could be detrimental.
* Decompensated heart failure with severe mitral regurgitation.
### Adverse Effects
Common adverse effects include tachycardia, arrhythmias, headache, nausea, vomiting, and peripheral vasoconstriction. Hypotension can also occur, especially with rapid dose increases.
### Key Drug Interactions
* **Anesthetics:** May potentiate hypotensive effects.
* **Beta-blockers:** May attenuate the desired positive inotropic effects.
* **Vasodilators:** Additive vasodilatory effects, increasing risk of hypotension.
* **Other Vasopressors:** Use with caution due to potential for additive effects and pressor overload.
### Monitoring
* Continuous hemodynamic monitoring (e.g., arterial line for blood pressure, central venous pressure, pulmonary artery catheter if available).
* Heart rate and rhythm.
* Urine output.
* Renal and hepatic function.
* Electrolytes.
### Clinical Pearls
* Initiate at the lowest effective dose and titrate slowly based on clinical response.
* Mega%252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252520cv is typically administered as a continuous infusion through a central venous catheter.
* Ensure adequate volume status before initiating therapy to avoid excessive hypotension.
* Consider concurrent use of other agents to manage underlying causes of shock or specific hemodynamic derangements.
***
*Disclaimer: This information is intended for clinical professionals and does not replace the need to consult the official prescribing information and current clinical guidelines for the most up-to-date and comprehensive details regarding Mega%252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252520cv.*
